Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECTION AMI: KAI-9803 in Acute Anterior STEMI Undergoing Primary PCI
2008-005140-16Phase 2Completed
- Sponsor
- KAI Pharmaceuticals
- Start
- Nov 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myocardial infarction (MI) comparing KAI-9803 with Placebo (2 arms). Primary endpoint: Primary: CK-MB AUC through 80 hours post-PCI in anterior STEMI cohort. Started Nov 2008; status: completed.
02
Drugs
delcasertib
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2008-005140-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005140-16.